YH1885L(Revaprazan) + Esomeprazole 20mg + placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-erosive Reflux Disease
Conditions
Non-erosive Reflux Disease
Trial Timeline
Jan 1, 2013 → Apr 1, 2014
NCT ID
NCT01750437About YH1885L(Revaprazan) + Esomeprazole 20mg + placebo
YH1885L(Revaprazan) + Esomeprazole 20mg + placebo is a phase 2 stage product being developed by Yuhan for Non-erosive Reflux Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01750437. Target conditions include Non-erosive Reflux Disease.
What happened to similar drugs?
0 of 5 similar drugs in Non-erosive Reflux Disease were approved
Approved (0) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01750437 | Phase 2 | Completed |
Competing Products
6 competing products in Non-erosive Reflux Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 40 |
| RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM | Eisai | Phase 3 | 40 |
| Omeprazole | AstraZeneca | Phase 3 | 40 |
| Omeprazole | AstraZeneca | Phase 3 | 40 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 2 | 29 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 3 | 34 |